Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from JTH on LinkedIn, about a recent article by Holly Dobbing et al, adding:
”Beyond DOACs: The Future of Anticoagulation
The recently highlighted article in the Journal of Thrombosis and Haemostasis explores novel and experimental anticoagulant strategies beyond current DOACs — a rapidly evolving field with profound clinical implications.
While direct oral anticoagulants (DOACs) have transformed thrombosis management, significant unmet needs remain:
- Patients with high bleeding risk
- Mechanical heart valves
- Advanced renal impairment
- Antiphospholipid syndrome
- Recurrent thrombosis despite standard therapy
Emerging therapeutic targets such as Factor XI and XIa inhibitors, RNA-based approaches, and next-generation selective pathway modulation aim to provide:
- Effective thrombosis prevention
- Reduced bleeding liability
- More precise coagulation control
For clinicians working in thrombosis and hemostasis, this represents a paradigm shift — moving from broad anticoagulation toward mechanism-refined, safer antithrombotic strategies.
As we continue strengthening thrombosis care systems in Armenia and globally, staying aligned with these innovations is essential for advancing patient safety and equity in treatment access.
Highly recommended reading for hematologists, cardiologists, and clinical researchers.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Novel and Experimental Anticoagulant Strategies Beyond Current DOACs
Emerging anticoagulation strategies explore contact pathway inhibition, fibrin targeting, and natural anticoagulant pathway enhancement to address DOAC limitations, promising safer thrombosis treatment with reduced bleeding risks for cardiovascular disease management.”
Title: Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants
Authors: Holly Dobbing, Katherine L. Webb, Robert Ariëns
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 1, 2026, 05:44Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?